Status:

UNKNOWN

A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Relapse in Patients With IBD

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

Inflammatory Bowel Diseases

Ulcerative Colitis

Eligibility:

All Genders

18+ years

Brief Summary

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition of the intestine, which results in diarrhea, rectal bleeding, urgency, weight loss and abdominal pain. The natural cours...

Detailed Description

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition of the intestine, which results in diarrhea, rectal bleeding, urgency, weight loss and abdominal pain. The natural cours...

Eligibility Criteria

Inclusion

  • Patient with Crohn's Disease
  • Aged ≥18 years old
  • Confirmed diagnosis of ileo-colonic Crohn's disease according to established clinical, endoscopic and histologic criteria
  • History of at least one flare with symptoms that required intervention within 24 months before screening
  • Stable doses of immunosuppressive agents for at least 3 months if these agents are required
  • In clinical remission for at least 3 months, defined as Harvey Bradshaw Index (HBI) score \< 4
  • Written informed consent obtained
  • Patient with Ulcerative Colitis
  • Aged ≥18 years old
  • Have a confirmed diagnosis of ulcerative colitis according to established clinical, endoscopic and histologic criteria
  • History of at least one flare with symptoms that required intervention within 24 months before screening
  • On stable regimen of 5-ASA for at least 3 months
  • In clinical remission for at least 3 months defined as partial Mayo score ≤ 1
  • Written informed consent obtained

Exclusion

  • Previous bowel surgery /stoma
  • On anti-TNF therapy
  • Malignant disease within 5 years
  • Use of probiotics, prebiotics or antibiotics in past 3 months
  • Terminal illness

Key Trial Info

Start Date :

January 28 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 28 2021

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04079335

Start Date

January 28 2019

End Date

January 28 2021

Last Update

September 6 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chinese University of Hong Kong

Hong Kong, Hong Kong